Abstract
Sildenafil (Viagra) prolongs repolarisation in cardiac muscle, an effect that could lead to ventricular fibrillation (VF). Sildenafil (2 mg kg -1) was given by mouth to 12 mongrel dogs and, 24 h later, these dogs were anaesthetised, thoracotomised and subjected to a 25 min occlusion of the anterior descending coronary artery. Haemodynamic parameters were similar in this and the control group, but there were fewer and less serious ventricular arrhythmias during occlusion in the sildenafil group (VF 17 vs 60%; ventricular premature beats 140 ± 52 vs 437 ± 127% and episodes of ventricular tachycardia 4.0 ± 3.2 vs 19.3 ± 7.7%, all P <0.05). However, reperfusion VF and indices of ischaemia severity (epicardial ST-segment mapping, inhomogeneity) were not modified by the drug. Sildenafil increased the QT interval, especially during ischaemia. Our conclusion is that ischaemia-induced ventricular arrhythmias are reduced by sildenafil, but this protection is less pronounced than that following cardiac pacing or exercise.
Original language | English |
---|---|
Pages (from-to) | 549-551 |
Number of pages | 3 |
Journal | British Journal of Pharmacology |
Volume | 141 |
Issue number | 4 |
DOIs | |
Publication status | Published - Feb 2004 |
Fingerprint
Keywords
- Delayed preconditioning
- Myocardial ischaemia
- Sildenafil
- Ventricular arrhythmias
- Viagra
ASJC Scopus subject areas
- Pharmacology
Cite this
Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24h after oral administration in dogs. / Nagy, Orsolya; Hajnal, Ágnes; Parratt, J.; Végh, A.
In: British Journal of Pharmacology, Vol. 141, No. 4, 02.2004, p. 549-551.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24h after oral administration in dogs
AU - Nagy, Orsolya
AU - Hajnal, Ágnes
AU - Parratt, J.
AU - Végh, A.
PY - 2004/2
Y1 - 2004/2
N2 - Sildenafil (Viagra) prolongs repolarisation in cardiac muscle, an effect that could lead to ventricular fibrillation (VF). Sildenafil (2 mg kg -1) was given by mouth to 12 mongrel dogs and, 24 h later, these dogs were anaesthetised, thoracotomised and subjected to a 25 min occlusion of the anterior descending coronary artery. Haemodynamic parameters were similar in this and the control group, but there were fewer and less serious ventricular arrhythmias during occlusion in the sildenafil group (VF 17 vs 60%; ventricular premature beats 140 ± 52 vs 437 ± 127% and episodes of ventricular tachycardia 4.0 ± 3.2 vs 19.3 ± 7.7%, all P <0.05). However, reperfusion VF and indices of ischaemia severity (epicardial ST-segment mapping, inhomogeneity) were not modified by the drug. Sildenafil increased the QT interval, especially during ischaemia. Our conclusion is that ischaemia-induced ventricular arrhythmias are reduced by sildenafil, but this protection is less pronounced than that following cardiac pacing or exercise.
AB - Sildenafil (Viagra) prolongs repolarisation in cardiac muscle, an effect that could lead to ventricular fibrillation (VF). Sildenafil (2 mg kg -1) was given by mouth to 12 mongrel dogs and, 24 h later, these dogs were anaesthetised, thoracotomised and subjected to a 25 min occlusion of the anterior descending coronary artery. Haemodynamic parameters were similar in this and the control group, but there were fewer and less serious ventricular arrhythmias during occlusion in the sildenafil group (VF 17 vs 60%; ventricular premature beats 140 ± 52 vs 437 ± 127% and episodes of ventricular tachycardia 4.0 ± 3.2 vs 19.3 ± 7.7%, all P <0.05). However, reperfusion VF and indices of ischaemia severity (epicardial ST-segment mapping, inhomogeneity) were not modified by the drug. Sildenafil increased the QT interval, especially during ischaemia. Our conclusion is that ischaemia-induced ventricular arrhythmias are reduced by sildenafil, but this protection is less pronounced than that following cardiac pacing or exercise.
KW - Delayed preconditioning
KW - Myocardial ischaemia
KW - Sildenafil
KW - Ventricular arrhythmias
KW - Viagra
UR - http://www.scopus.com/inward/record.url?scp=1842610702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842610702&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0705658
DO - 10.1038/sj.bjp.0705658
M3 - Article
C2 - 14744808
AN - SCOPUS:1842610702
VL - 141
SP - 549
EP - 551
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
SN - 0007-1188
IS - 4
ER -